BioAtla is developing selectively-targeting antibodies based on very interesting science.
However, it is a new IPO, and current prices and cash reserves are not conducive to investment.
This is one to add to your watchlist.
Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker.